It seems to be another hint in a series of recent
Post# of 72440
"A new direction, a new understanding of what’s going on, actually growing the company, not shrinking it.”
https://investorshangout.com/post/view?id=555...z62U5D7Hfl
I think you are right to believe Locust Walk was retained to guide IPIX through a deal for oral Brilacidin for Ulcerative Colitis. We should receive some real news after the BDD trial.
The first Brilacidin trial for UC showed an unexpected benificial response. The BDD trial is to confirm the effective delivery of Brilacidin to the large and small intestines.
My bet is we will see investment from other parties after the BDD trial. Then IPIX will have the necessary financing for the later stage FDA and EU trials.
IMO, 2020 should be a good year for IPIX and its shareholders.
GLTA Farrell